Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine

Publication date: May 2018
Source:Cancer/Radiothérapie, Volume 22, Issue 3
Author(s): H.A.H. Mohamed, M.A. Salem, M.S. Elnaggar, A. Gabr, A.M. Abdelrheem
PurposeA prospective phase II study carried out to evaluate hypofractionated radiotherapy with concurrent gemcitabine for bladder preservation in the elderly patient with bladder cancer.Patients and methodsThirty-one patients were enrolled, age ≥65years, diagnosed with transitional cell carcinoma of the urinary bladder, after a maximum safe transurethral resection of a bladder tumour. They received 52.5Gy in 20 fractions using 3D conformal radiotherapy with concurrent 100mg/m² gemcitabine weekly as a radiosensitizer.ResultsAll patients completed their radiation therapy course, while seven patients received their chemotherapy irregularly due to grade 3 toxicities. Twenty-five patients (80.6%) achieved a complete response. At 2-years, overall survival was 94.4% and disease-free survival was 72.6%. T3 and residual after transurethral resection are factors that adversely affect disease-free survival.ConclusionHypofractionated radiotherapy and gemcitabine as a radiosensitizer in elderly as organ preservation for transitional cell carcinoma bladder cancer have acceptable toxicity profile with good response rate and disease-free survival, keeping salvage cystectomy for persistence or recurrence of invasive cancer.



https://ift.tt/2yLFeip